Mostrar el registro sencillo del ítem
Diagnostic and prognostic value of B4GALT1 hypermethylation and its clinical significance as a novel circulating cell-free DNA biomarker in colorectal cancer
dc.contributor.author | Picardo, F. | |
dc.contributor.author | Romanelli, A. | |
dc.contributor.author | Muinelo Romay , Laura | |
dc.contributor.author | Mazza, T. | |
dc.contributor.author | Fusilli, C. | |
dc.contributor.author | Parrella, P. | |
dc.contributor.author | Barbazán, J. | |
dc.contributor.author | López López, Rafael | |
dc.contributor.author | Barbano, R. | |
dc.contributor.author | De Robertis, M. | |
dc.contributor.author | Taffon, C. | |
dc.contributor.author | Bordoni, V. | |
dc.contributor.author | Agrati, C. | |
dc.contributor.author | Costantini, M. | |
dc.contributor.author | Ricci, F. | |
dc.contributor.author | Graziano, P. | |
dc.contributor.author | Maiello, E. | |
dc.contributor.author | Muscarella, L. A. | |
dc.contributor.author | Fazio, V. M. | |
dc.contributor.author | Poeta, M. L. | |
dc.date.accessioned | 2021-11-30T11:12:22Z | |
dc.date.available | 2021-11-30T11:12:22Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/31635093 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/15780 | |
dc.description.abstract | Epigenetic modifications of glyco-genes have been documented in different types of cancer and are tightly linked to proliferation, invasiveness, metastasis, and drug resistance. This study aims to investigate the diagnostic, prognostic, and therapy-response predictive value of the glyco-gene B4GALT1 in colorectal cancer (CRC) patients. A Kaplan-Meier analysis was conducted in 1418 CRC patients (GEO and TCGA datasets) to assess the prognostic and therapy-response predictive values of the aberrant expression and methylation status of B4GALT1. Quantitative methylation-specific PCR (QMSP) and droplet digital quantitative methylation-specific PCR (dd-QMSP) were respectively used to detect hypermethylated B4GALT1 in metastasis and plasma in four cohorts of metastatic CRC cases (mCRC). Both the downregulated expression and promoter hypermethylation of B4GALT1 have a negative prognostic impact on CRC. Interestingly a low expression level of B4GALT1 was significantly associated with poor cetuximab response (progression-free survival (PFS) p = 0.01) particularly in wild-type (WT)-KRAS patients (p = 0.03). B4GALT1 promoter was aberrantly methylated in liver and lung metastases. The detection of hypermethylated B4GALT1 in plasma of mCRC patients showed a highly discriminative receiver operating characteristic (ROC) curve profile (area under curve (AUC) value 0.750; 95% CI: 0.592-0.908, p = 0.008), clearly distinguishing mCRC patients from healthy controls. Based on an optimal cut-off value defined by the ROC analysis, B4GALT1 yield a 100% specificity and a 50% sensitivity. These data support the potential value of B4GALT1 as an additional novel biomarker for the prediction of cetuximab response, and as a specific and sensitive diagnostic circulating biomarker that can be detected in CRC. | en |
dc.language.iso | eng | es |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Diagnostic and prognostic value of B4GALT1 hypermethylation and its clinical significance as a novel circulating cell-free DNA biomarker in colorectal cancer | en |
dc.type | Artigo | es |
dc.authorsophos | Picardo, F. | |
dc.authorsophos | Romanelli, A. | |
dc.authorsophos | Muinelo-Romay, L. | |
dc.authorsophos | Mazza, T. | |
dc.authorsophos | Fusilli, C. | |
dc.authorsophos | Parrella, P. | |
dc.authorsophos | Barbazán, J. | |
dc.authorsophos | Lopez-López, R. | |
dc.authorsophos | Barbano, R. | |
dc.authorsophos | De Robertis, M. | |
dc.authorsophos | Taffon, C. | |
dc.authorsophos | Bordoni, V. | |
dc.authorsophos | Agrati, C. | |
dc.authorsophos | Costantini, M. | |
dc.authorsophos | Ricci, F. | |
dc.authorsophos | Graziano, P. | |
dc.authorsophos | Maiello, E. | |
dc.authorsophos | Muscarella, L. A. | |
dc.authorsophos | Fazio, V. M. | |
dc.authorsophos | Poeta, M. L. | |
dc.identifier.doi | 10.3390/cancers11101598 | |
dc.identifier.pmid | 31635093 | |
dc.identifier.sophos | 31808 | |
dc.issue.number | 10 | es |
dc.journal.title | Cancers (Basel) | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía médica | es |
dc.page.initial | 1598 | es |
dc.relation.publisherversion | https://res.mdpi.com/d_attachment/cancers/cancers-11-01598/article_deploy/cancers-11-01598.pdf | es |
dc.rights.accessRights | openAccess | es |
dc.subject.keyword | IDIS | es |
dc.subject.keyword | CHUS | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 11 | es |